Address And Details

70 South Lake Avenue, Suite 930 , Pasadena, CA 91101
Fund Manager J. Dale Harvey
Manager Tenure 11 Years 10 Months

Strategy And Objective

The Poplar Forest Partners Fund (the Partners Fund ) seeks to achieve long-term growth of capital. The Partners Fund seeks to deliver superior, risk-adjusted returns over full market cycles, by investing primarily in the common stocks of underappreciated companies and industries. A full market cycle is deemed to be a multi-year period including a period of material increase in the U.S. stock market (a bull market ) and a period of material decline in the U.S. stock market (a bear market ). The Fund generally focuses on 25 to 35 companies with (i) an investment grade debt rating, (ii) a history of paying common stock dividends, and (iii) a market capitalization among the top 1,000 companies in the United States. The Partners Fund is managed using a long-term approach to security selection. Investments will generally be made with an intended investment horizon of three years, although individual investments may be held for shorter or longer time periods. The Adviser evaluates investment opportunities using bottom up, fundamental analysis, paying particular attention to the following factors: expected future profits; expected sustainable revenue and/or asset growth; expected cash investment needed to support expected growth; normalized earnings and free cash flow after considering Items 1 through 3 above; and valuation relative to normalized earnings and free cash flow after giving consideration to growth potential and financial strength. The Partners Fund may also invest up to 25% of its net assets in government and corporate debt securities of any maturity. Of this 25%, no more than 10% of the Fund s net assets will be invested in investment grade corporate debt and no more than 5% of the Fund s net assets will be invested in non-investment grade (i.e., junk bonds) corporate debt. The Fund also may invest up to 20% of its net assets in foreign equity securities. Additionally, up to 15% of the Fund s net assets may be invested in a combination of convertible securities, options on stocks, warrants and rights and other non-money market fund investment companies.

Net Asset Value

as of 5:04 PM ET 10/18/2021

Performance

  • 1 Week
  • +1.06%
  • 1 Month
  • +3.47%
  • 3 Months
  • +6.34%
  • 1 Yr Return
  • +56.41%
  • 5 Yr Return
  • +25.64%

Equity Sector Breakdown

Finance 27.32%
Technology 14.23%
Health 13.63%
RetailTrade 11.73%
Energy 8.46%
ConsumerDurables 6.29%
Utilities 4.16%
IndustrialCyclical 3.68%
NonDurables 2.90%
Services n/a

Asset Allocation

Asset Type % Of Allocation
Stocks 97.31%
Cash 0.00%
Bonds 0.00%
Preferred 0.00%
Convertible 0.00%
Other 0.00%
ForeignStocks 0.00%
ForeignBonds 0.00%
ForeignHedged 0.00%
Total Net Assets 24.10 M

Risk Measures

Criteria 3 Years 5 Years 10 Years
Alpha -10.25 -10.06 -6.17
Beta 1.29 1.25 1.23
R Squared 0.82 0.76 0.77
Std Deviation 26.80 21.86 18.63
Sharpe Ratio 0.37 0.44 n/a

Purchase Information

as of 4:56 PM ET 10/15/2021
Minimum Initial $25000
Minimum Additional $1000
Minimum Initial IRA $5000

Performance

Timeframe Average Annual Current Performance Monthly As Of 09/30/2021 Average Annual Current Performance Quarterly As Of 09/30/2021 Avg Annual Current Performance Monthly As Of 09/30/2021 Avg Annual Current Performance Quarterly As Of 09/30/2021
1 Year
  • +60.26%
  • +60.26%
+60.26% +60.26%
3 Year
  • +7.05%
  • +7.05%
+7.05% +7.05%
10 Year
  • +12.63%
  • +12.63%
+12.63% +12.63%
Life Of Fund
  • +10.45%
  • +10.45%
+10.45% +10.45%

Top 10 Holdings

Symbol Company Name % Of Assets
WFC WELLS FARGO & CO 4.82%
ALLY ALLY FINANCIAL INC 4.55%
AAP ADVANCE AUTO PARTS 4.55%
MUR MURPHY OIL CORP 4.30%
CVS CVS HEALTH CORP 4.28%
EQH EQUITABLE HOLDINGS INC 4.28%
CVX CHEVRON CORP 4.17%
NFG NATIONAL FUEL GAS CO 4.16%
DXC DXC TECHNOLOGY COMPANY 4.08%
ALL ALLSTATE CORPORATION 3.99%

Recent Articles from TheStreet

After Red-hot IPO, Chinese Biotech Firm Kintor Eyes Blockbuster Drugs For Prostate Cancer, Sex Hormone-related Hair Loss

Atea Pharma Stock Plunges After COVID Treatment Trial Disappoints; Merck Jumps

Atea Pharmaceuticals could shed more than $2 billion in value Tuesday after the drugmaker said a mid-stage trial of its developing COVID treatment failed to meet expectations.

What to know about Cloudflare's Upcoming IPO

Investing in the Cloud: Consider Cloudflare and Digital Ocean

Cloud-software growth stocks have been a bright spot in an uncertain market. Investors might look closely at Cloudflare and Digital Ocean.

Philip Morris International Lead

Philip Morris Ekes Out Third-Quarter Earnings Beat

Philip Morris posts a third-quarter earnings beat as sales of its smokeless non-tobacco products continue strong, though cautions on supply chain impact.

The Travelers Companies Lead

Travelers Posts Third Quarter Earnings Beat on Record Net Written Premiums

Travelers Companies posts third-quarter earnings that exceed analysts’ forecasts as a drop in what it calls ‘catastrophic losses’ offsets record net written premiums.

Lufax is set to make the biggest splash on the NYSE by a Chinese company since e-commerce giant Alibaba's IPO in 2014. Photo: Reuters

Stock Market Today: Dow Gains On Earnings Strength; Housing Starts Disappoint

Solid third quarters continue to power stocks higher Tuesday, even as growth and inflation signals remain stubbornly persistent as oil prices top $85 a barrel in overnight trading.

Procter & Gamble Is Under Siege From an Activist Investor

Procter & Gamble Stock Slips After Q1 Earnings Beat; 2022 Forecast Unchanged

Procter & Gamble held its 2022 forecasts in place, seeing sales growth of between 2% and 4%, following stronger-than-expected first quarter earnings.

No More Tears for Johnson & Johnson?

Johnson & Johnson Stock Gains as Vaccine Sales Boost Q3 Earnings, 2021 Forecasts

Johnson & Johnson said it sees 2021 vaccine sales of $2.5 billion, with overall revenues rising to between $94.1 billion to $94.6 billion, following its Q3 earnings beat.

Stock Market Lead

Stocks Gain, SEC GameStop Report, Rent The Runway IPO - 5 Things You Must Know

Stocks edge higher ahead of earnings; SEC says GameStop surge powered by believers; FDA set to approve "mix & match' COVID boosters; DraftKings faces Entain bid deadline and Rent the Runway seeks $1.3 billion valuation in Nasdaq IPO.